UCB News

UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, with operations in nearly 40 countries. Guided by the belief that it should be inspired by patients and driven by science, the company researches, develops and delivers medicines and support solutions for people living with severe neurological and autoimmune diseases. Its areas of focus include conditions such as epilepsy and psoriasis, alongside other significant medical needs.

UCB’s work brings together scientific research, clinical development, patient insights and digital health approaches. The company also shares research through scientific publications and clinical studies, and collaborates with academic institutions and biotechnology companies to advance innovation. Its portfolio and development pipeline span several therapy areas.

Beyond medicines, UCB offers UCBCares, a patient support program that provides practical, personal guidance to people with chronic diseases and healthcare professionals throughout the treatment journey. The company also highlights equitable access to medicines, patient engagement, sustainability, inclusion and ethical business practices as part of its broader approach to creating value and improving quality of life.